Naratriptan Beta

Naratriptan, the active ingredient in Naratriptan Beta, is a Triptan (5‑HT1B/1D receptor agonist) presented as a tablet for oral use. It treats acute migraine attacks with or without aura in adults.

GNH USA supplies Naratriptan Beta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan is indicated for the acute treatment of migraine, a neurovascular headache disorder.

- Migraine with aura: provides rapid relief of headache pain and associated symptoms. - Migraine without aura: reduces headache intensity and duration. - Acute migraine attacks: aborts attacks when taken at onset.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: transient light‑headedness. - Drowsiness: feeling unusually sleepy. - Dry mouth: reduced salivation. - Fatigue: general tiredness. - Paresthesia: tingling sensations.

Serious or Rare Side Effects: - Chest pain: possible cardiac ischemia. - Hypertension: elevated blood pressure. - Serotonin syndrome: agitation, hyperthermia, tremor. - Severe allergic reaction: rash, swelling, breathing difficulty. - Cardiac arrhythmia: irregular heartbeat. - Ischemic events: stroke or myocardial infarction.

Before prescribing Naratriptan, clinicians should evaluate patient‑specific risk factors.

- Assess cardiovascular risk: review history of coronary artery disease, angina, or stroke. - Avoid in uncontrolled hypertension: monitor blood pressure prior to use. - Caution with serotonergic agents: evaluate for potential serotonin syndrome. - Use the lowest effective dose: follow prescriber guidance for individual patients. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Naratriptan may interact with several drug classes; careful review is required.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Ergot derivatives: additive vasoconstriction may cause ischemia. - Other triptans: excessive vasoconstriction. - SSRIs and SNRIs: potential serotonin syndrome. - CYP1A2 inhibitors (e.g., fluvoxamine): may increase plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise concentrations. - CYP3A4 inducers (e.g., carbamazepine): may reduce efficacy. - Antihypertensives: may enhance blood‑pressure‑lowering effect. - Non‑serotonergic antidepressants: monitor for additive central effects. - Alcohol: may increase dizziness and sedation.